Polyplus-transfection SA, a developer of innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics, has introduced jetOPTIMUS, a new reagent for powerful nanoparticle DNA transfection.
“As cell and gene therapies become more advanced and complex, this increases the need to address DNA transfection of very challenging cells. To increase efficiency in hard-to-transfect cells, scientists have to use ever-more advanced reagents,” said Patrick Erbacher, the company’s CSO. “We recognised the need to combine the efficiency, safety and morphology requirements of mammalian cell transfection. To date, the market has not supplied what is expected today to fulfil all needs. Polyplus-transfection believes jetOPTIMUS will equip academics in the most advanced cell and gene therapy based research with the best solution.”
The reagent has been designed to be primarily used in academic research in the field of mammalian cells, especially hard-to-transfect cells. Polyplus-transfection says the reagent will result in the most efficient mammalian cell transfection product on the market, maximising gene expression, thus ensuring improved cell viability and morphology after transfection for more relevant data, and that the requirement of a minimal reagent volume and DNA quantity will considerably increase cost efficiency: the cost per reaction will be decreased by up to seven times when compared to other market leading products, the company claims.
For further information about Polyplus-transfection visit www.polyplus-transfection.com
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!